Bio-Techne Corporation
Analysis
Across four calls one story holds: Bio-Techne's tools keep selling, but small biotech, US academia and two big cell-therapy customers all cut back at once, so growth slid from mid-single digits into decline. The next two quarters decide whether that reverses. How much of the biotech funding rebound has reached the order book?
- The market improved on paper while revenue got worse.
Biotech funding rose and China grew for a fourth straight quarter, but organic growth still slipped to down 2%. Management admits it got the cart ahead of the horse on the timing, and nothing improves until biotech spending returns. How much of the four-quarter China recovery came from tariff pull-forward?
- Two cell-therapy customers stopped ordering, and that pause ends.
Both won FDA Fast Track, which sped their trials up but meant they had already stockpiled reagents for Phase III. Strip them out and GMP proteins grew nearly 50%. The drag shrinks again next quarter, then disappears in fiscal 2027. How many cell-therapy programs beyond those two are now in late-stage trials?
- Profit held up on cost cuts and a divestiture, not on sales.
Margin expanded 100 basis points in each of the first two quarters even as sales fell, because selling the Exosome unit removed a business that was losing money. The third quarter slipped, and management cut its year-end margin goal.
- Large pharma keeps buying at a double-digit pace. Those customers have grown steadily for six quarters, so the company has a floor under it while smaller buyers waver.
- The two cell-therapy customers resume buying before long. Their pause cut growth by three points last quarter, so part of the recovery arrives with no help from the market.
- The core reagent business turns back up as funding converts. It is more than half of sales, so its recovery is what turns the company's growth positive.
- Large pharma slows as US drug-pricing pressure reaches its budgets. These customers fund the company today, so if they trim research spending the steady part of the business wobbles too.
- Biotech funding does not turn into orders on schedule. The upturn has been pushed into fiscal 2027, so another year of flat sales is the base case rather than a bad patch.
- The margin gains are coming from cost cuts, not more sales. Cost cuts are holding profit up, so a slump forces a choice between protecting profit and paying for new products.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 23 | May 13 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Jun 2 | Jul 6 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Jun 30 | Jul 6 |
Ro Khanna Democratic · House · CA-17 | Purchase | ≥$1K | May 15 | Jun 9 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Apr 13 | May 11 |
Congressional trading data provided by QuiverQuant
How Bio-Techne turned $1.2B of revenue into $251.9M of operating income.
| Revenue | ||
|---|---|---|
| Consumables | $985.1M | ▲ 1.32% YoY |
| Instruments | $110.6M | ▼ 1.30% YoY |
| Royalty | $25.0M | ▲ 5.48% YoY |
| Total revenue | $1.2B | |
| Gross profit | $799.1M | 65.8% |
| Operating income | $251.9M | 20.7% |